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Abstract
Background:  The primary objective was to determine whether consumption of conjugated
linoleic acids (CLAs) affected the fecal microbiota composition, fecal enzyme activity or fecal
composition.
Methods: Human subjects consumed (1 L/day) cows' milk (4% fat) containing (5 mg/g fat) cis-9,
trans-11 CLA (CONT), (32 mg/g fat) cis-9, trans-11 CLA (NAT) and (32 mg/g fat) trans-10, cis-12
CLA and cis-9, trans-11 CLA (SYN) for 8 weeks, in addition to their normal diet. Milk feeding
periods were separated by 4 week washout periods. Fecal samples were obtained at the beginning
( d a y  0 )  a n d  t h e  e n d  ( d a y  5 6 )  o f  e a c h  m i l k  f e e d i n g  p e r i o d .  F e c a l  s a m p l e s  w e r e  a n a l y s e d  f o r
microbiological profile, enzyme activity, pH and short chain fatty acid content.
Results:  Samples taken at day 0 and day 56 indicated that the numbers of lactobacilli  and
bifidobacteria significantly decreased after consumption of all experimental milks; total aerobes, total
anaerobes, enterobacteria, and enterococci + streptococci did not change. At day 56, the activities
of β-glucosidase, nitroreductase, and urease enzymes had decreased compared to samples taken
on day 0 for all treatments. β-glucuronidase activity did not change. Fecal pH and ammonia content
did not change.
Conclusion: It was concluded that observed changes could have been attributed to increased milk
intake; no differences could be attributed to consumption of the different CLAs.
Background
A variety of positional and geometrical isomers of linoleic
acid are included in the general term conjugated linoleic
acids (CLAs). Rumen bacteria produce CLAs [1,2] from
dietary linoleic acid, and as a result, red meats and dairy
products are the main sources of cis-9, trans-11 CLA in the
human diet. In foods, CLAs are in the triglyceride form.
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Experiments in which humans were fed CLAs have
reported loss of body weight [3], reductions of % body fat
and sagittal abdominal diameter [3-5], and a positive
impact on some coronary artery disease risk factors [6].
Various mechanisms have been presented to explain the
mode of action of CLAs, either in animals or humans [4-
9].
The gastrointestinal tract is inhabited by a large and
diverse microbiota [10,11]. This microbial population is
relatively stable, but changes occur due to age, disease sta-
tus, use of medications such as antibiotics, and diet [12-
14]. It has been speculated that changes to the intestinal
microbiota could explain alterations in lipid metabolism
[15,16]. In vitro experiments have shown that CLAs can
inhibit growth of some bacteria and alter bacteria mem-
brane lipid composition [17]. However, very few studies
have been published in which the effects of the lipid com-
ponent of the diet on the gastrointestinal (GI) tract micro-
biota have been reported [18-20].
It is believed that the microbiota that inhabits the GI tract
influences a wide variety of digestive, metabolic, and
immune functions [21]. Carman et al. [22] pointed out
that changes in the intestinal microflora population may
not be easy to achieve, but in any case, it is changes in
'microflora associated characteristics' (MACs) that are bet-
ter indicators of effects of diet on the host. A change in
enzymatic activity may be one MAC that has long term
implications on health. The activities of various fecal
enzymes have been reported to be influenced by dietary
fat [23], carbohydrates [23-27], and consumed bacteria
[25,28,29].
β-glucuronidase activity in feces comes from Bacteriodes
and other bacteria. β-glucuronidase hydrolyzes a variety
of glucuronides, liberating carcinogenic aglycones. Fecal
β-glucosidase activity also comes mainly from Bacteriodes,
but many streptococci and lactobacilli also have high β-
glucosidase activity. β-glucosidase is responsible for the
hydrolysis of plant β-glycosides, releasing into the intesti-
nal lumen aglycones which are mutagenic and carcino-
genic [30-32]. Nitroreductase enzyme acts on aromatic
nitro-compounds resulting in the formation of harmful
amines [33]. Urease enzyme can act on urea releasing
ammonia and carbon dioxide; high urease activities have
been found in some Eubacteria and Peptococcus bacteria
[34]. Ammonia has been shown to promote the growth of
tumors in the colon; it facilitates the growth of pathogenic
bacteria and contributes to mucosal tissue damage [35].
Decreases in fecal β-glucuronidase, β-glucosidase, nitrore-
ductase and urease activities are thus considered desirable
because of their links to the production of carcinogens
[36].
Goldin & Gorbach [37] reported that fecal β-glucuroni-
dase, nitroreductase and azoreductase enzyme activities
did not change when human subjects consumed 500 ml
of low fat milk per day for 30 days. Conversely, in one
Yakult feeding trial reported by Tanaka [38], β-glucuroni-
dase enzyme activity decreased in 4 of 10 control subjects,
β-glucosidase enzyme activity decreased in 3 of 10 control
subjects, and reductase enzyme activity decreased in 3 of
10 control subjects consuming unfermented milk (240
ml/day) compared to pre-experiment values. In a second
trail, the reductions of β-glucuronidase and β-glucosidase
were statistically significant in subjects consuming unfer-
mented milk (300 ml/day). Feeding lactose (20 g/day or
40/day) did not affect fecal β-glucosidase or β-glucuroni-
dase activities in elderly subjects [24].
Lactobacilli along with bifidobacteria have received much
attention as ingredients in probiotic products [39-41].
Feeding milk containing lactobacilli has been shown to
successfully increase lactobacilli numbers [42,43]. How-
ever, feeding just lactose 20 g/day or 40 g/day has been
shown to reduce significantly lactobacilli numbers [24].
It is apparent that CLAs are potent bioactive lipid ingredi-
ents in many foods. As CLAs pass down through the GI
tract, they may be bringing about changes to the intestinal
microbiota, which may in turn be contributing to their
whole body effects.
This study was undertaken to determine whether the con-
sumption of CLAs effected the intestinal microbiota pop-
ulation composition and function. Fecal samples were
collected from subjects who had consumed different
forms and amounts of CLA to determine whether the con-
sumption of the experimental milks affected the numbers
of various fecal bacteria, fecal enzyme activity or fecal
composition. Data presented here were obtained during a
larger experiment in which the effects of CLA consump-
tion on lipid metabolism and body composition were
studied.
Methods
Subject selection
Selection criteria for subjects in the study were: moder-
ately hyperlipidemic (LDL cholesterol > 2.5 mmol/L),
overweight (BMI 25–30 kg/m2) men and women between
the ages of 30 and 60. Volunteers with thyroid disease,
diabetes mellitus, kidney disease, or liver disease, who
smoked, who had previous symptoms of lactose intoler-
ance, consumed large amounts of alcohol or who were
taking antibiotics were excluded.
Twice during the experiment, subjects filled out a ques-
tionnaire to determine their normal consumption of milk
and dairy products.Nutrition Journal 2007, 6:15 http://www.nutritionj.com/content/6/1/15
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Milk samples
Three types of milk were used in the feeding trial: 4% fat
homogenized cows' milk, containing 5 mg/g fat cis-9,
trans-11 CLA (CONT); 4% fat homogenized cows' milk
naturally enriched in cis-9, trans-11 CLA (32 mg/g fat) by
feeding cows with sunflower oil (NAT) or 4% fat homog-
enized cows' milk that was enriched with trans-10, cis-12
CLA (32 mg/g fat) and cis-9, trans-11 CLA (32 mg/g fat) in
the form of triglycerides (Natural Co., Norway), (SYN).
For the analysis of milk fatty acids, methyl esters were pre-
pared by base-catalyzed transmethylation according to
the method of Chouinard et al.[44]. Fatty acid analyses
were carried out with a gas chromatograph (HP 5890A
Series II, Hewlett Packard, Palo Alto, CA) equipped with a
100-m CP-Sil 88 capillary column (i.d., 0.25 mm; film
thickness, 0.20 μm; Chrompack, Middelburg, the Nether-
lands) and a flame ionization detector. At the time of the
sample injection the column temperature was 80°C for 1
min, then ramped at 2°C/min to 215°C and maintained
for 30 min. Inlet and detector temperatures were 220°C
and 230°C, respectively. The split ratio was 100:1. The
flow rate for hydrogen carrier gas was 1 mL/min. Fatty
acid peaks were identified, quantified and the gas chroma-
tograph calibrated using pure methyl ester standards (Nu
Chek Prep, Elysian, MN).
Experimental design
The experiment was a three feeding phase (8 weeks each),
cross-over design separated by 2 washout periods (4
weeks each). The single-blind clinical trial was carried out
at the Mary Emily Clinical Research Unit, McGill Univer-
sity. In each feeding phase, one third of the subjects con-
sumed either 1 L/day of CONT, NAT or SYN. The type of
experimental milk consumed was changed in each feeding
phase, until all subjects had consumed all three milks.
Milk samples were coded; subjects did not know the code.
Fecal samples were collected on days 0 and 56 of each
feeding phase. All samples were identified by subject
number only until analyses were complete.
Microbiological analyses
Fecal samples were immediately refrigerated after collec-
tion and then they were mixed with a storage solution
(pH 7.2) consisting of (per L): 1 g yeast extract, 1 g
KH2PO4, 0.15 g K2HPO4, 0.15 g NHCl, 1 g NaCl, 0.6 g
MgCl26H2O, 0.1 g KCl, and 0.5 g cysteine-HCl, and stored
at -20°C until enumeration.
Aliquots of diluted fecal samples were spread on the fol-
lowing aqueous agar media: Columbia blood agar (CBA)
media (Oxoid Company, Basingstoke, UK) containing
5% sterile defibrinated blood (Quélab, Montreal, QC,
Canada) incubated for total anaerobes; Columbia agar
base (BBL, Becton Dickinson, Cockeysville, MD, USA)
950 mL containing lactose 5 g/L and cysteine hydrochlo-
ride 0.5 g/L and 50 mL NPNL stock containing neomycin
(Sigma, St. Louis, MO, USA) 100 mg/L, paromomycin sul-
phate (Sigma) 200 mg/L for bifidobacteria; 500 mL Difco
Lactobacilli MRS broth (Becton Dickenson Co., Sparkes
MD, USA) containing cysteine hydrochloride 0.5 g/L, bro-
mocresol green (Sigma) 0.05 g/L – pH 5.0, 10 mL vanco-
mycin hydrochloride (Sigma) solution, 500 mL agar
(Difco, Detroit, MI) 40 g/L for lactobacilli; MacConkey
agar (Difco) for enterobacteriaceae; m-Enterococcus agar
(Difco) for enterococci and streptococci; sulphite poly-
myxin milk (SPM) agar 930 mL containing tryptone
(Difco) 15 g/L, yeast extract (Difco) 10 g/L, ferric citrate
(Sigma) 0.5 g/L, agar (Difco) 18 g/L, 5 mL 5% Na2SO3, 10
mL 0.1% colistin sulphate (Sigma), 4 mL 1% neutral red
solution (supplier), 50 mL sterile whole cows' milk for
clostridia; Schaedler agar (Becton Dickinson, Sparks, MD)
for total aerobes. Microbial data were expressed as log
CFU/g wet feces.
Enzyme assays
Thawed fecal samples were homogenized (Basic T25; IKA
Co., Wilmington, NC, USA) in phosphate buffer (0.1 M;
pH 7.0), sonicated 2 × 1 min (Branson Sonicator Model
2210) and centrifuged 15 min at 500 × g (Dynac II, Becton
Dickinson). The supernatant was used for enzyme assays.
β-Glucuronidase (EC 3.2.1.31; substrate phenolphthalin
mono β-D-glucuronic acid; Sigma, St. Louis, MO), β-glu-
cosidase (EC 3.2.1.21; substrate p-nitrophenyl-β-D glu-
copyranoside; Sigma) and nitroreductase (substrate m-
nitrobenzoic acid; Sigma) enzyme activities were meas-
ured in fecal extracts using the methods detailed by Gol-
din & Gorbach [45]. The nitroreductase assays were
carried out in an anaerobic chamber. Urease (EC 3.5.1.5;
substrate urea) activity was measured using the method of
Ling et al.[46].
The protein concentration of fecal extracts used in enzy-
matic assays was determined using the method of Lowry
(Sigma), with bovine serum albumin as a standard. All
enzyme activities were expressed in units of product pro-
duced/mg fecal protein/min.
Fecal composition analyses
The pH of fecal slurry samples (1 g feces, 10 mL distilled
water, mixed with a tissue homogenizer [IKA Labortech-
nik, Wilmington, NC], 1 min) was measured using a
Accumet Model 25 pH meter (Fisher Scientific, Nepean,
ON, Canada), and an Orion pH probe (Fisher Scientific).
Ammonia concentrations of the fecal enzyme supernatant
samples were measured using an Orion Ammonia probe
(Fisher Scientific). The short chain fatty acid (SCFA) con-
tent of water extracts of fecal material were measured
using HPLC techniques [47]. Peaks were identified byNutrition Journal 2007, 6:15 http://www.nutritionj.com/content/6/1/15
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comparing retention times to authentic standards pur-
chased from Sigma Chemical Co. (St. Louis, USA).
Ethics
Informed consent was obtained in writing from all sub-
jects prior to the start of the experiment. The experimental
protocol was approved by the McGill University Ethics
Committee.
Statistical analyses
Data were used only when samples from both day 0 and
day 56 of a feeding phase were analysed. Analyses of vari-
ance (ANOVA) were carried out using the PROC GLM
procedure of SAS version 8.02, with milk type (CONT,
NAT, SYN), sample day (0 or 56) – main effects, and inter-
actions included in the model. Microbial counts and pH
data were analysed as actual counts and hydrogen ion
concentration respectively; data in tables and graphs are
the log transforms. Inability to produce a sample and con-
tamination (by urine) reduced the number of samples
analysed. Legends to tables and figures indicate number
of data points contributing to each mean.
Since the initial ANOVA showed no CLA treatment effects,
post facto the data from the three CLA milk groups (CONT,
NAT, SYN) at day 0 and at day 56 were combined, and an
ANOVA on the combined data performed (COMBINED
DATA).
Results
Table 1 shows the fatty acid compositions of the milks
that were fed. The CONT milk had the lowest levels of cis-
9, trans-11 CLA, and no trans-10, cis-12 CLA, while the
SYN milk had the highest levels of these two fatty acids.
Fifteen subjects successfully finished the entire experi-
ment. Three subjects dropped out mid-way through the
interventions. Two subjects, one female and a male, dis-
Table 1: Milk fat content and fatty acid profile of experimental milks
Experimental Milk
CONT NAT SYN
Milk fat content, % 3.9 3.9 4.0
Fatty acid, % by weight
C4:0 4.99 4.44 4.07
C6:0 2.45 1.93 2.18
C8:0 1.40 1.00 1.28
C10:0 2.93 1.87 2.70
C12:0 3.31 2.09 3.02
C14:0 10.79 8.41 10.14
C14:1 cis-9 1.07 0.94 0.99
C15:0 1.17 1.00 1.07
C16:0 32.42 20.47 31.18
C16:1 cis-9 1.64 1.06 1.50
C17:0 0.58 0.47 0.52
C18:0 9.46 13.00 8.97
C18:1 trans-6 + trans-7 + trans-8 0.30 0.82 0.26
C18:1 trans-9 0.23 0.71 0.23
C18:1 trans-10 0.34 1.19 0.33
C18:1 trans-11 0.92 7.17 0.77
C18:1 trans-12 0.49 1.53 0.45
C18:1 cis-11 0.85 0.65 0.82
C18:1 cis-12 0.27 1.39 0.26
C18:1 cis-13 0.10 0.10 0.09
C18:1 trans-16 + cis-14 0.34 .066 0.30
C18:1 cis-15 0.09 0.27 0.07
C18:2 trans-11, cis-15 0.10 0.24 0.13
C18:2 cis-9, cis-12 1.87 2.23 2.04
C20:0 0.14 0.16 0.16
C18:3 cis-9, cis-12, cis-15 0.38 0.38 0.39
C18:2 cis-9, trans-11 0.42 2.92 3.28
C18:2 trans-10, cis-12 n.d.1 n.d. 3.03
1. n.d. = not detectedNutrition Journal 2007, 6:15 http://www.nutritionj.com/content/6/1/15
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continued during the first phase of the clinical trial
because of personal reasons. Another female subject dis-
continued during the second phase of the clinical trial
because of pregnancy. Compliance was tested by asking
the subjects to return the used and unused milk contain-
ers.
The two surveys questioning milk product consumption
that were carried out during the course of the experiment
(data not presented) indicated that all of the subjects had
low daily intakes of milk (skim, 1% fat, 2% fat, whole
milk) and dairy products (butter, cheese, yogurt, ice-
cream, dairy creamers) as part of their normal diet. During
the CLA-milk part of the experiment, subjects were con-
suming an additional litre of milk per day.
Table 2 is a summary of the microbial analyses of fecal
samples collected on days 0 and 56 of the three feeding
phases. Within each diet group, there were large inter-sub-
ject variations for the enumerated bacteria. Generally,
samples contained more total anaerobes than aerobes.
ANOVA analyses indicated that the type of milk con-
sumed did not have any effect on the fecal microbial pro-
files. At the end of the 56 day feeding phases, there were
no statistical differences in the number of fecal total aer-
obes, total anaerobes, enterobacteria and entrococci +
streptococci and clostridia compared to the numbers enu-
merated in samples taken at day 0. However, at the end of
56 days, fecal samples contained significantly fewer lacto-
bacilli and bifidobacteria compared to samples taken at
day 0.
Table 2: Fecal microbiological profile1 of subjects at Days 0 and 56 of consuming experimental milks
Statistical Analyses
Bacteria Day 0 Day 56 Milk Type2 Sample Day3 MT*SD4
T o t a l  A e r o b e s N SN SN S
CONT 8.62 8.56
NAT 8.50 8.54
SYN 8.48 8.53
T o t a l  A n a e r o b e s N SN SN S
CONT 9.59 10.41
NAT 11.17 10.72
SYN 9.50 10.30
Lactobacilli NS *** NS
CONT 6.89 5.24
NAT 6.52 4.99
SYN 8.07 5.10
Bifidobacteria NS *** NS
CONT 7.07 6.44
NAT 7.06 6.23
SYN 7.00 6.25
E n t e r o b a c t e r i a N SN SN S
CONT 7.52 5.75
NAT 8.40 5.39
SYN 7.05 5.37
E n t e r o + S t r e p N SN SN S
CONT 7.28 4.92
NAT 6.03 4.76
SYN 6.43 5.32
C l o s t r i d i a N SN SN S
CONT 4.84 5.04
NAT 5.04 5.12
SYN 4.91 4.97
1. bacteria counts expressed as log CFU/g wet feces
2. difference due to milk type (CONT vs NAT vs SYN)
3. difference due to sample day (DAY 0 vs DAY 56)
4. interaction – milk type and sample dayNutrition Journal 2007, 6:15 http://www.nutritionj.com/content/6/1/15
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The results of the fecal enzyme analyses are shown in Fig-
ures 1, 2, 3, 4. The enzyme activity for each CLA milk
group (CONT, NAT, SYN) is plotted showing values for
samples from day 0 and day 56. When ANOVA analyses
indicated that there were no statistical differences between
any of the different CLA milk groups, all milk group data
were combined, and the results of sampling day (0 vs 56)
are shown in the fourth pair of bars (COMBINED DATA).
This combining of the data had the advantage of increas-
ing the statistical power of the ANOVA test. The activities
of β-glucosidase, reductase, and urease in fecal material all
significantly declined in samples obtained at day 56 of the
feeding phase, compared to samples obtained at day 0
when the COMBINED DATA were analysed. There was no
change in fecal β-glucuronidase activity over time.
Fecal pH was not affected by either the kind of CLA milk
consumed or the sampling day (0 vs 56). The average pH
of all groups was between 7.1 and 7.5. Likewise, ammonia
levels measured in fecal samples were not different in sub-
jects consuming different CLA milks or between samples
taken at days 0 and 56. Average fecal ammonia concentra-
tions levels ranged from 2–6 mM/mL of fecal extract.
HPLC analyses of fecal samples obtained at day 0 and day
56 of the feeding periods contained acetic acid, propionic
acid, butyric acid, and isobutyric acid. The small number
of samples analysed prevented rigorous statistical analy-
ses. At day 0, only 50% of the samples analysed contained
measurable amounts of lactic acid, but 100% of 56 day
samples from the same subjects contained lactic acid.
Discussion
The make-up of the microbial population that inhabits
the human GI tract is influenced by several factors includ-
ing diet and diet constituents [11,12,22]. Bifidobacteria
have been the subject of much research because of the
belief that they are probiotic bacteria, and therefore die-
tary components should be identified that increase bifido-
bacteria numbers [47-50]. Several studies have shown that
significant changes (increases) in fecal bifidobacteria
numbers can be achieved by the addition of fructans to
the diet [24,51-54].
In our study where subjects were consuming an additional
1 L of milk per day, bifidobacteria numbers significantly
declined in all three diet groups over the course of the 56
day feeding phases, perhaps indicating that milk per se is
affecting this family of bacteria. This is supported by Tan-
aka [38] who reported bifidobacteria numbers declined
(compared to pre-experiment values) in 4 of 10 and 5 of
10 control subjects who were receiving 240 mL/d and 300
Fecal glucosidase enzyme activity in subjects consuming milk  containing 5 mg/g fat cis-9, trans-11 CLA – CONT; 32 mg/g  fat cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis-12  CLA (32 mg/g fat) and cis-9, trans-11 CLA – SYN Figure 2
Fecal glucosidase enzyme activity in subjects consuming milk 
containing 5 mg/g fat cis-9, trans-11 CLA – CONT; 32 mg/g 
fat cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis-12 
CLA (32 mg/g fat) and cis-9, trans-11 CLA – SYN. Number of 
samples contributing to mean = 11. Data from the 3 different 
milk groups (CONT, NAT, SYN) for Day 0 and Day 56 = 
COMBINED DATA. Number of samples contributing to 
mean = 33. Enzyme activity units – mg p-nitrophenol pro-
duced/min/mg fecal protein.
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Fecal glucuronidase enzyme activity in subjects consuming  milk containing 5 mg/g fat cis-9, trans-11 CLA – CONT; 32  mg/g fat cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis- 12 CLA (32 mg/g fat) and cis-9, trans-11 CLA – SYN Figure 1
Fecal glucuronidase enzyme activity in subjects consuming 
milk containing 5 mg/g fat cis-9, trans-11 CLA – CONT; 32 
mg/g fat cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis-
12 CLA (32 mg/g fat) and cis-9, trans-11 CLA – SYN. Number 
of samples contributing to mean = 12. Data from the 3 differ-
ent milk groups (CONT, NAT, SYN) for Day 0 and Day 56 = 
COMBINED DATA. Number of samples contributing to 
mean = 36. Enzyme activity units – mg phenolphthalein pro-
duced/min/mg fecal protein.
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mL/d (respectively) of unfermented milk. In addition, we
also found that lactobacilli numbers significantly
declined, which may have been the result of the consump-
tion of an additional 48 g lactose/day during the experi-
ment.
In this experiment, where adult subjects consumed an
additional 1 L of milk during the feeding portions of the
experiment,  β-glucosidase, nitroreductase and urease
activities were all significantly decreased. These effects on
fecal enzyme activities occurred in subjects who normally
consumed low levels of milk and dairy products. It is not
possible at this time to attribute changes in fecal enzyme
activity to the changes in the population of one or more
fecal bacteria. However, the long term effects of reducing
the activities of these enzymes in particular may be desir-
able.
A reduction in the pH of intestinal digesta has been
reported to be desirable [55]. Some feeding trials have
reported a lowering of fecal pH [20] but, as we have
reported here, other studies have found no changes in
fecal pH due to changes in diet [24,26,56]. The use of fecal
pH as an indicator of fermentation and acidity in the
colon has been questioned [26].
Ammonia in not usually found in high concentrations in
fecal material, because any ammonia generated in the
intestinal lumen from bacterial breakdown of nitroge-
nous substances – proteins, urea – is normally quickly
absorbed. High levels of intestinal ammonia are not desir-
able, and it has been shown that the bacterial production
of ammonia can be reduced by lowering the pH or adding
lactose, glucose or lactulose to the fermentation media
[57]. In our subjects, the reduction of the activity of fecal
urease did not result in lowered fecal ammonia concentra-
tions.
The effects observed in this feeding trial could be attrib-
uted to the increased consumption of milk. At this time, it
is not possible say what component of milk caused the
observed effects. Our data indicate that consumption of
milks with different types and levels of CLAs do not
change the intestinal microbiota composition or func-
tion. Changes in fecal enzyme activity due to increased
milk consumption may have long term health benefits.
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Fecal urease enzyme activity in subjects consuming milk con- taining 5 mg/g fat cis-9, trans-11 CLA – CONT; 32 mg/g fat  cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis-12 CLA  (32 mg/g fat) and cis-9, trans-11 CLA – SYN Figure 4
Fecal urease enzyme activity in subjects consuming milk con-
taining 5 mg/g fat cis-9, trans-11 CLA – CONT; 32 mg/g fat 
cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis-12 CLA 
(32 mg/g fat) and cis-9, trans-11 CLA – SYN. Number of sam-
ples contributing to mean = 12. Data from the 3 different 
milk groups (CONT, NAT, SYN) for Day 0 and Day 56 = 
COMBINED DATA. Number of samples contributing to 
mean = 36. Enzyme activity units – mmoles ammonia pro-
duced/min/mg fecal protein.
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Fecal nitroreductase enzyme activity in subjects consuming  milk containing 5 mg/g fat cis-9, trans-11 CLA – CONT; 32  mg/g fat cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis- 12 CLA (32 mg/g fat) and cis-9, trans-11 CLA – SYN Figure 3
Fecal nitroreductase enzyme activity in subjects consuming 
milk containing 5 mg/g fat cis-9, trans-11 CLA – CONT; 32 
mg/g fat cis-9, trans-11 CLA – NAT; 32 mg/g fat trans-10, cis-
12 CLA (32 mg/g fat) and cis-9, trans-11 CLA – SYN. Number 
of samples contributing to mean = 8. Data from the 3 differ-
ent milk groups (CONT, NAT, SYN) for Day 0 and Day 56 = 
COMBINED DATA. Number of samples contributing to 
mean = 24. Enzyme activity units – ug m-aminobenzoic acid-
produced/min/mg fecal protein.
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